PharmaBoardroom

US Pharma Could do a Lot More to Embrace the Consumer

PwC's Kelly Barnes examines how the US pharmaceutical sector is having to rethink its relationship with consumers, experimenting with new and…

Chinese PD-1 Cancer Drugs: Global Competition for Big Pharma

PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began…

Forging a New Path to Commercialization for Cell and Gene…

Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in…

Shooting For the Stars: The Evolution in Outcome-Based Payment…

Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful…

Further Predictions for 2019 – Tech, Value-Based Pricing…

As we move further into 2019, Emmanuel Fombu, MD, MBA: Author and Global Commercial Strategy and Digital Innovation Leader at Johnson and Johnson,…

The Future of Biosimilars in the USA

Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in…

Government Sector Organisations: France

The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure…

China Healthcare in 2019: Sprinting a Marathon

Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look…

How Beneficial Is The Recent Price Control Exemption For…

Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates, a leading Indian law firm. In this…